PRNewsWire
16 Jul 2026, 11:30 UTC · 17w ago
Verdict
Headline takes no side. We score GLMD +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Galmed has developed a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, capable of penetrating heart tissue.
More positive than 93% of claims this week
Galmed is collaborating with Barcode Nanotech to use an AI-enabled in vivo screening platform to optimize nanoparticle delivery to specific cardiac cells.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
Galmed continues to prioritize the commercialization of CG-100 and the clinical development of Aramchol for GI oncology indications.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company announced a breakthrough development of a novel cardiac-targeted LNP formulation for its SCD1 inhibitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
15h ago
+12.7%
Price agrees with the score
$4.63 vs $4.11 close before publication (Jul 15) · not market-adjusted
GLMD chart →
